Latest Pharmacy News

Biome Australia Limited has reported a robust half-year performance, with revenues climbing nearly 40% and net profit more than doubling, driven by strong product momentum and strategic investments.

McPherson’s Limited has confirmed a $3.3 million total tax benefit following amended assessments by the ATO, linked to deductible costs from a strategic alliance announced in 2022.

Wesfarmers has reported a 9.3% rise in net profit after tax to $1.6 billion for H1 2026, driven by robust performances in Bunnings, Kmart Group, and lithium operations. The company also announced a 7.4% increase in its interim dividend amid ongoing cost pressures and strategic AI partnerships.

Vita Life Sciences has reported a strong FY2025 with record revenue of $93.3 million and net profit after tax rising 18.8%, while declaring a 14.0 cents per share dividend.

Gratifii Limited has secured a five-year strategic partnership with Marketplacer to deploy an AI-powered digital rewards marketplace, aiming to significantly expand its product range and monetisation capabilities.

ECS Botanics has partnered with Nimbus Health to distribute its medicinal cannabis products across Germany, marking its entry into Europe's largest cannabis market. The launch of the OzSun brand is set for April 2026, with premium Terphogz strains to follow later in the year.

EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

Careteq Limited has agreed to sell its Embedded Health Solutions business for $5 million, aiming to strengthen its balance sheet and focus on expanding its home medication review platform amid ongoing tax disputes.

Adheris Health has expanded its operating cost reduction program, aiming for more than 30% savings by FY27, while refocusing on high-growth pharmaceutical categories and enhancing its AI-powered patient engagement platform.

EVE Health Group has transitioned from development to commercial rollout, delivering first patient prescriptions of Dyspro™ and completing initial manufacturing of Libbo™, supported by a $1.1 million capital raise.

Tissue Repair’s December quarter update reveals a cautious path forward for its Phase 3 TR987 trial amid slow patient recruitment, while its TR Pro+ product line gains momentum through a new distributor partnership and upcoming product launches.